ストックスクリーナーアプリを入手
4.33
4.59%
0.19
アフターアワーズ：
4.12
-0.21
-4.85%
前日終値:
$4.14
開ける：
$3.9
24時間の取引高:
221.41K
Relative Volume:
1.26
時価総額：
$34.13M
収益：
$2.34M
当期純損益:
$-30.37M
株価収益率:
-1.4716
EPS:
-2.9424
ネットキャッシュフロー:
$-23.42M
1週間 パフォーマンス:
-7.87%
1か月 パフォーマンス:
-15.10%
6か月 パフォーマンス:
-24.70%
1年 パフォーマンス:
-21.98%
1日の値動き範囲:
$3.90
$4.365
1週間の範囲:
$3.90
$4.94
52週間の値動き範囲:
$3.4962
$16.25
Radiopharm Theranostics Ltd Adr Stock (RADX) Company Profile
Compare RADX vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RADX
Radiopharm Theranostics Ltd Adr
|
4.33 | 32.64M | 2.34M | -30.37M | -23.42M | -2.9424 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Radiopharm Theranostics Ltd Adr Stock (RADX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-12 | 開始されました | B. Riley Securities | Buy |
Radiopharm Theranostics Ltd Adr (RADX) 最新ニュース
Radiopharm Theranostics LimitedSponsored ADR (NASDAQ:RADX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI) and Shattuck Labs (STTK) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Ocugen (OCGN) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI) - The Globe and Mail
Radiopharm Theranostics Doses First Patient in Phase 1/2a Trial of 177Lu-BetaBart - TipRanks
Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Beyond Air (XAIR) - The Globe and Mail
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Fifth Third Bancorp (NASDAQ:FITB) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Hartford Multifactor Emerging Markets ETF (NYSEARCA:ROAM) Short Interest Up 110.6% in January - Defense World
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Sees Significant Increase in Short Interest - Defense World
Short Interest in Azitra, Inc. (NYSEAMERICAN:AZTR) Expands By 112.1% - Defense World
GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update - Defense World
iShares Environmentally Aware Real Estate ETF (NASDAQ:ERET) Sees Significant Increase in Short Interest - Defense World
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Icon (ICLR) and Perspective Therapeutics (CATX) - The Globe and Mail
Radiopharm Theranostics (NASDAQ:RADX) versus Bolt Biotherapeutics (NASDAQ:BOLT) Head-To-Head Survey - Defense World
Analysts Offer Insights on Healthcare Companies: Radiopharm Theranostics Limited Sponsored ADR (RADX) and Resmed (RMD) - The Globe and Mail
Radiopharm Theranostics (ASX:RAD) Prepares for Multiple 2026 Readouts with Firm Cash Position - Kalkine Media
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates - GlobeNewswire Inc.
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates - Sahm
Stevanato Group S.p.A. (NYSE:STVN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Radiopharm Theranostics (NASDAQ:RADX) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Radiopharm Theranostics Lifts Stake in MD Anderson Joint Venture to 87.5% as Lead B7H3 Drug Enters Clinic - TipRanks
RAD Increases Ownership in Radiopharm Ventures to 87.5% - Sahm
RADX: Interim Readout Achieves 92% Concordance - Research Tree
Equities Analysts Issue Forecasts for RADX FY2026 Earnings - Defense World
RADX FY2026 EPS Reduced by Brookline Capital Management - MarketBeat
Analysts’ Top Healthcare Picks: Foghorn Therapeutics (FHTX), Eton Pharmaceuticals (ETON) - The Globe and Mail
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com India
Radiopharm Theranostics (NASDAQ:RADX) Receives Buy Rating from B. Riley - Defense World
Buy Rating for Radiopharm Theranostics Limited Driven by Promising Clinical Developments and Growth Potential - TipRanks
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com UK
Radiopharm Theranostics (NASDAQ:RADX) Earns "Buy" Rating from B. Riley - MarketBeat
Dow Falls 50 Points; US Adds 64,000 Jobs In November - Benzinga
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
US stock market crash today: Dow, S&P 500, Nasdaq slide deep into the red — why is the stock market down today? - MSN
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.09% - Investing.com UK
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.09% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.09% - Investing.com India
Radiopharm (RADX) Sees Slight Pessimism From Analysts - Finviz
US stock market crash today: Dow, S&P 500, Nasdaq slide deep into the red — why is the stock market down t - The Economic Times
Radiopharm Theranostics interim data shows 92% reach endpoint in RAD101 study - Investing.com Canada
Radiopharm Theranostics stock soars after positive brain metastases trial data - Investing.com
Radiopharm Theranostics stock soars after positive brain metastases trial data By Investing.com - Investing.com India
Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases - Sahm
Book value per share of Radiopharm Theranostics Limited Sponsored ADR – NASDAQ:RADX - TradingView — Track All Markets
Radiopharm Theranostics Ltd Adr (RADX) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):